NCT05843799View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of ILB-202

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 16, 2023

Primary Completion Date

October 4, 2023

Study Completion Date

October 4, 2023

Conditions
Healthy
Interventions
DRUG

ILB-202

Single i.v. infusion

DRUG

Placebo

Single i.v. infusion

Trial Locations (1)

Unknown

Adelaide, Adelaide

Sponsors
All Listed Sponsors
lead

ILIAS Biologics Inc.

INDUSTRY